

Targeting Novel Approaches to Treatment

Michelle Lofwall, MD




Background

- Only 20% of persons with opioid use disorder (OUD) receive specialty addiction treatment
- Among those, only 37% receive FDA-approved medication for OUD
- There are many reasons for low treatment uptake, BUT it is not because our treatments are ineffective
 - Treatment decreases illicit opioid use, infection, crime, and death
 - What's holding us back? Stigma, discrimination, and concerns about diversion limit uptake
 - Diversion: unauthorized rerouting or misappropriation of medication to someone other than the person for whom it was intended



Buprenorphine Basics

- Most commonly prescribed OUD treatment
- Sublingual (under the tongue) tablets/films or buccal (cheek) films most often prescribed as daily medication
- Partial mu-opioid agonist FDA approved in 2002 for OUD treatment
 - High affinity and binds tightly to receptor
 - Not as strong as a full agonist 1
 - Long half-life






Buprenorphine: Why It Works

- Therapeutic efficacy is provided because it:
 - Relieves opioid withdrawal that often drives use
 - Decreases craving for opioids
 - Provides opioid blockade (of euphoria and respiratory depression). The blockade makes it a waste of money and time to use, so we see less illicit opioid use over time
- Overall, it gives people a fighting chance to make other important changes in their lives, so they can enter into and maintain remission and work a recovery program...
- But this requires access and adherence to medication



Probuphine®: Solid Matrix Subdermal Implant FDA-approved May 2016



Four rods provide sustained release of buprenorphine for up to six months. Intended for clinically stable patients already on 8 mg SL daily.

80 mg buprenorphine/rod



Probuphine Results

• 177 randomized; 166 completed (93.8% retention = WOW!!!)

Responder rate	Implant	Sublingual tablets	P value
Primary Analysis			
- 4 of 6 months without illicit opioid use	81/84 (96.4%)	78/89 (87.6%)	< 0.001
Secondary Analysis			
- 6 months of illicit opioid abstinence	72/84 (85.7%)	64/89 (71.9%)	0.03

• Less need for tablets = less opportunity for non-adherence, misuse and diversion



CAM2038: Subcutaneous Buprenorphine


<u>Overview</u>

- FluidCrystal® nano-technology
- Weekly and monthly injections
- Multiple doses
- Room temperature
- Small volume, thin needle

Advantages

- Steady and sustained blood levels
- Less concern about misuse and diversion
- Improved adherence







CAM2038 Study Results

• Phase 2 and 3 studies successful

- Quickly alleviated opioid withdrawal
- Suppressed craving for opioids
- Blocked effects of illicit opioids
- Reduced illicit opioid use
- Potential utility to further increase access to treatment for several reasons:
 - Attractive to providers
 - Attractive to new settings (ex: justice, emergency rooms, and hospitals)
 - Attractive to payors
 - Attractive to patients



Summary

- We have many opportunities for novel treatment development.
- The opioid epidemic started here in Appalachia.
- It is very appropriate that UK scientists and clinicians are leading the way to improve the treatment of this devastating disorder.